Form 4: ResMed Inc. Executive Michael J. Rider Sells Shares Under 10b5-1 Plan

Michael J. Rider, Global General Counsel of ResMed Inc., sold 64 shares of common stock at $242.42 per share on February 3, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On February 3, 2025, Michael J. Rider, the Global General Counsel of ResMed Inc., sold 64 shares of ResMed Common Stock.
• The sale was executed at a price of $242.42 per share.
• The transaction was conducted under a Rule 10b5-1 plan adopted on May 11, 2024.
• Following the transaction, Rider directly owns 8,974 shares of ResMed Common Stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged 10b5-1 plan and doesn't necessarily indicate a change in the executive's confidence in the company.

Industry Context

Insider trading activity is always closely watched by investors as it can provide signals, though often not definitive, about management's view of the company's prospects. Sales under a 10b5-1 plan are generally less informative since they are pre-arranged.

Stakeholder Impact

• The sale of shares by a company executive may cause some investors to scrutinize the company's performance, but the impact is likely to be minimal given the small number of shares sold and the existence of a pre-arranged trading plan.

Key Dates

Keywords

Form 4, ResMed, RMD, Insider Trading, Michael J. Rider, 10b5-1 plan, Stock Sale, Global General Counsel